If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

  • This share is currently suspended. It was suspended at a price of 0.01
  • There is currently no data for VRS

Placing to raise £454,822

8 Nov 2023 07:00

RNS Number : 7079S
Versarien PLC
08 November 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS AMENDED) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (AS AMENDED). UPON PUBLICATION OF THIS ANNOUNCMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

8 November 2023

 

Versarien plc

 

("Versarien" or the "Company")

 

Placing to raise £454,822

 

Versarien plc (AIM: VRS), the advanced materials engineering group, announces it has raised £454,822 (before expenses) by way of a placing (the "Placing") of 165,389,817 new ordinary shares in the capital of the Company ("Placing Shares") at a price of 0.275 pence per share (the "Placing Price").

 

Highlights

 

· Versarien has raised £454,822, before expenses, through the placing of 165,389,817 new ordinary shares in the capital of the Company at a price of 0.275 pence per share

· The net proceeds of the Placing will be used for corporate and working capital purposes, together with providing bridge finance to extend the Company's cash runway ahead of any funds received from asset sales

· The issue of the Placing Shares is within existing authorities granted by shareholders at the general meeting of the Company held on 30 October 2023 and therefore no shareholder approval is required for the Placing

 

Use of Proceeds and Turnaround Strategy

 

The net proceeds of the Placing will be used for corporate and working capital purposes, together with providing bridge finance to extend the Company's cash runway ahead of any funds received from asset sales.

 

Versarien continues to pursue its stated turnaround strategy:

· to maintain and strengthen the Company's scientific teams;

· use its know-how in construction and textiles to be a manufacturing light operation;

· to licence Versarien's technology, brands and manufacturing understanding; and

· divest non-core activities.

 

As previously announced, the mature businesses and the intellectual property and plant acquired from Hanwha Aerospace in 2020 continue to be marketed for sale and the Company is progressing discussions with a number of interested parties. The sale process for AAC Cyroma Limited, a manufacturer of moulded products, is the most advanced. However, the timing of any asset sales and the total quantum of the funds that may be received remains uncertain.

 

Stephen Hodge, Chief Executive Officer of Versarien, commented:

 

"As we have previously announced, the Company requires further funding to continue its turnaround strategy and we welcome the investor interest in this Placing. We continue to focus on this strategy, pursuing an encouraging pipeline of commercial and R&D projects, as well as technology licencing opportunities. We look forward to updating shareholders on continuing progress in the coming months."

 

Admission and Total Voting Rights

 

Application has been made for admission of the Placing Shares to be admitted to trading on AIM ("Admission") on or around 13 November 2023. The Placing Shares will rank pari passu in all respects with the Company's existing ordinary shares. Following Admission, the total number of ordinary shares in the Company in issue will be 496,169,507. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

 

For further information please contact:

 

Versarien

Stephen Hodge, Chief Executive Officer

Chris Leigh, Chief Financial Officer

 

c/o IFC

SP Angel Corporate Finance (Nominated Adviser and Broker)

Matthew Johnson, Adam Cowl

+44 (0)20 3470 0470

 

 

IFC Advisory Limited (Financial PR and Investor Relations)

Tim Metcalfe, Zach Cohen

+44 (0) 20 3934 6630

 

About Versarien:

 

The strategy of Versarien plc (AIM:VRS) is to be a development led advanced materials company focussed on specific sectors that will lead to a light manufacturing and licensing model.

 

For further information please see: http://www.versarien.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEUPGWWGUPWPUM
Date   Source Headline
9th Feb 20267:00 amRNSCancellation - Versarien Plc
6th Jan 20261:34 pmRNSAppointment of Administrators
19th Dec 20254:36 pmRNSUpdate on NOIA
19th Dec 20254:36 pmRNSUpdate on NOIA
15th Dec 20253:53 pmRNSUpdate on the Disposal of AAC Cyroma Limited
12th Dec 20257:00 amRNSUpdate on NOIA and Change of Registered Office
1st Dec 20257:30 amRNSSuspension - Versarien plc
1st Dec 20257:00 amRNSIntention to Appoint Administrators, Suspension
26th Nov 20257:00 amRNSUpdate - Proposed Disposal of the Company's Assets
31st Oct 20258:48 amRNSProposed Disposal of the Company’s Assets
29th Sep 20252:32 pmRNSCorporate Update
10th Sep 20251:00 pmRNSCorporate Update
29th Aug 20252:19 pmRNSCorporate Update
21st Aug 20257:00 amRNSStrategic Investment and Joint Venture Update
11th Aug 20257:00 amRNSCorporate Update
5th Aug 202511:03 amRNSHolding(s) in Company
29th Jul 20257:00 amRNSCorporate Update
22nd Jul 202510:55 amRNSSettlement of Legal Claims
4th Jul 20257:00 amRNS-RSouth American Polygrene™ Themoplastics Agreements
30th Jun 20253:03 pmRNSInterim Results
19th Jun 20252:34 pmRNSBuilding for Humanity – Contract Update
4th Jun 202511:49 amRNSHolding(s) in Company
2nd Jun 20252:03 pmRNSHolding(s) in Company
30th May 202510:19 amRNSHolding(s) in Company
30th May 20257:00 amRNSTotal Voting Rights
29th May 20253:29 pmRNSHolding(s) in Company
29th May 202510:20 amRNSHolding(s) in Company
27th May 202511:59 amRNSHolding(s) in Company
27th May 202511:02 amRNSHolding(s) in Company
23rd May 20259:38 amRNSHolding(s) in Company
22nd May 202511:56 amRNSHolding(s) in Company
21st May 202510:58 amRNSHolding(s) in Company
20th May 202511:11 amRNSHolding(s) in Company
14th May 20257:00 amRNSPlacing to raise £425,000
2nd May 202511:00 amRNSUpdate on Legal Claims
28th Apr 20251:04 pmRNSResult of AGM
27th Mar 20257:00 amRNSAudited Results for year ended 30 September 2024
24th Mar 202511:24 amRNSResult of General Meeting
10th Mar 20257:00 amRNS-RGraphinks™ supply agreement with Montana Química
5th Mar 20257:00 amRNSNotice of General Meeting
3rd Mar 20257:00 amRNSCompletion of Sale of Korean Assets
28th Feb 20257:00 amRNSTotal Voting Rights
27th Feb 20257:00 amRNSInnovate UK Loan Deed of Variation
10th Feb 20258:35 amRNSHolding(s) in Company
28th Jan 20252:36 pmRNSPlacing to raise £246k
30th Dec 202412:00 pmRNSUpdate on Sale of Korean Assets
13th Dec 20242:58 pmRNSHolding(s) in Company
13th Dec 202411:50 amRNSHolding(s) in Company
13th Dec 202410:11 amRNSHolding(s) in Company
13th Dec 20247:00 amRNS€804,000 Grant Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.